Clinical Trial: Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Multicenter, Randomized Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in the Treatment of Cellulitis or Erysipelas
Brief Summary:
This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters:
- Time to erythema margin cessation to progress
- Time to defervescence
- Time to hospital discharge following relief of the presenting cellulitis or erysipelas
- Degree of improvement of the following signs and symptom of cellulitis or erysipelas including
- Degree of improvement of cellulitis-related pain and swelling as reported by subjects
Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin will be described.
Detailed Summary: same as above
Sponsor: Cubist Pharmaceuticals LLC
Current Primary Outcome: investigating the differences in speed and degree of symptom resolution between CUBICIN and vancomycin
Original Primary Outcome:
Current Secondary Outcome: frequency of Serious Adverse Events between daptomycin and vancomycin will be described
Original Secondary Outcome:
Information By: Cubist Pharmaceuticals LLC
Dates:
Date Received: February 21, 2006
Date Started: February 2006
Date Completion:
Last Updated: October 10, 2016
Last Verified: October 2016
